Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer

被引:104
作者
Flores, L. M. [1 ,2 ]
Kindelberger, D. W. [3 ,5 ]
Ligon, A. H. [3 ,4 ,5 ]
Capelletti, M. [1 ]
Fiorentino, M. [4 ]
Loda, M. [3 ,4 ,5 ]
Cibas, E. S. [3 ,5 ]
Jaenne, P. A. [1 ,3 ]
Krop, I. E. [1 ,3 ]
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Univ Massachusetts, Dept Biol, Boston, MA 02125 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
关键词
circulating tumour cells; breast cancer; lung cancer; HER2; FISH; PERIPHERAL-BLOOD; SURVIVAL; PROGRESSION; MUTATIONS;
D O I
10.1038/sj.bjc.6605676
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Circulating tumour cells (CTCs) offer a non-invasive approach to obtain and characterise metastatic tumour cells, but their usefulness has been limited by low CTC yields from conventional isolation methods. METHODS: To improve CTC yields and facilitate their molecular characterisation we compared the Food and Drug Administration-approved CellSearch Epithelial Kit (CEK) to a simplified CTC capture method, CellSearch Profile Kit (CPK), on paired blood samples from patients with metastatic breast (n=75) and lung (n=71) cancer. Molecular markers including Human Epidermal growth factor Receptor 2 (HER2) were evaluated on CTCs by fluorescence in situ hybridisation (FISH) and compared to patients' primary and metastatic cancer. RESULTS: The median cell count from patients with breast cancer using the CPK was 117 vs 4 for CEK (P<0.0001). Lung cancer samples were similar; CPK: 145 cells vs CEK: 4 cells (P<0.0001). Recovered CTCs were relatively pure (60-70%) and were evaluable by FISH and immunofluorescence. A total of 10 of 30 (33%) breast cancer patients with HER2-negative primary and metastatic tissue had HER2-amplified CTCs. CONCLUSION: The CPK method provides a high yield of relatively pure CTCs, facilitating their molecular characterisation. Circulating tumour cells obtained using CPK technology demonstrate that significant discordance exists between HER2 amplification of a patient's CTCs and that of the primary and metastatic tumour. British Journal of Cancer (2010) 102, 1495-1502. doi:10.1038/sj.bjc.6605676 www.bjcancer.com (C) 2010 Cancer Research UK
引用
收藏
页码:1495 / 1502
页数:8
相关论文
共 19 条
[1]   Highly efficient circulating tumor cell isolation from whole blood and label-free enumeration using polymer-based microfluidics with an integrated conductivity sensor [J].
Adams, Andre A. ;
Okagbare, Paul I. ;
Feng, Juan ;
Hupert, Matuesz L. ;
Patterson, Don ;
Goettert, Jost ;
McCarley, Robin L. ;
Nikitopoulos, Dimitris ;
Murphy, Michael C. ;
Soper, Steven A. .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2008, 130 (27) :8633-8641
[2]   Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases [J].
Allard, WJ ;
Matera, J ;
Miller, MC ;
Repollet, M ;
Connelly, MC ;
Rao, C ;
Tibbe, AGJ ;
Uhr, JW ;
Terstappen, LWMM .
CLINICAL CANCER RESEARCH, 2004, 10 (20) :6897-6904
[3]   Circulating tumor cells versus imaging - Predicting overall survival in metastatic breast cancer [J].
Budd, G. Thomas ;
Cristofanilli, Massimo ;
Ellis, Mathew J. ;
Stopeck, Allison ;
Borden, Ernest ;
Miller, M. Craig ;
Matera, Jeri ;
Repollet, Madeline ;
Doyle, Gerald V. ;
Terstappen, Leon W. M. M. ;
Hayes, Daniel F. .
CLINICAL CANCER RESEARCH, 2006, 12 (21) :6403-6409
[4]   Circulating tumor cells, disease progression, and survival in metastatic breast cancer [J].
Cristofanilli, M ;
Budd, GT ;
Ellis, MJ ;
Stopeck, A ;
Matera, J ;
Miller, MC ;
Reuben, JM ;
Doyle, GV ;
Allard, WJ ;
Terstappen, LWMM ;
Hayes, DF .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (08) :781-791
[5]   Is there a role for circulating tumor cells in the management of breast cancer? [J].
Hayes, Daniel F. ;
Smerage, Jeffrey .
CLINICAL CANCER RESEARCH, 2008, 14 (12) :3646-3650
[6]   Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival [J].
Hayes, Daniel F. ;
Cristofanilli, Massimo ;
Budd, G. Thomas ;
Ellis, Matthew J. ;
Stopeck, Alison ;
Miller, M. Craig ;
Matera, Jeri ;
Allard, W. Jeffrey ;
Doyle, Gerald V. ;
Terstappen, Leon W. W. M. .
CLINICAL CANCER RESEARCH, 2006, 12 (14) :4218-4224
[7]  
*JOHNS JOHNS O CD, 2008, MKG1417 JOHNS JOHNS
[8]   Detection of mutations in EGFR in circulating lung-cancer cells [J].
Maheswaran, Shyamala ;
Sequist, Lecia V. ;
Nagrath, Sunitha ;
Ulkus, Lindsey ;
Brannigan, Brian ;
Collura, Chey V. ;
Inserra, Elizabeth ;
Diederichs, Sven ;
Iafrate, A. John ;
Bell, Daphne W. ;
Digumarthy, Subba ;
Muzikansky, Alona ;
Irimia, Daniel ;
Settleman, Jeffrey ;
Tompkins, Ronald G. ;
Lynch, Thomas J. ;
Toner, Mehmet ;
Haber, Daniel A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) :366-377
[9]   HER-2 gene amplification can be acquired as breast cancer progresses [J].
Meng, SD ;
Tripathy, D ;
Shete, S ;
Ashfaq, R ;
Haley, B ;
Perkins, S ;
Beitsch, P ;
Khan, A ;
Euhus, D ;
Osborne, C ;
Frenkel, E ;
Hoover, S ;
Leitch, M ;
Clifford, E ;
Vitetta, E ;
Morrison, L ;
Herlyn, D ;
Terstappen, LWMM ;
Fleming, T ;
Fehm, T ;
Tucker, T ;
Lane, N ;
Wang, JQ ;
Uhr, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (25) :9393-9398
[10]   Circulating tumor cells (CTCs): Detection methods and their clinical relevance in breast cancer [J].
Mostert, Bianca ;
Sleijfer, Stefan ;
Foekens, John A. ;
Gratama, Jan Willem .
CANCER TREATMENT REVIEWS, 2009, 35 (05) :463-474